



Corporate Presentation

June 2026

NASDAQ: EPRX

Forward Looking Statements

The safety, efficacy and effectiveness of Eupraxia Pharmaceuticals Inc.'s (the "Company" or "Eupraxia") products (including EP-104) are still under investigation and market authorization has not yet been granted by Health Canada in Canada or the US Food and Drug Administration in the United States. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied.

FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.

Forward-looking statements in this presentation include, but are not limited to, statements regarding the Company's business strategy and objectives, including current and future plans and opportunities, expectations and intentions; the Company's clinical trials, including expected releases of data; the potential of the Company's product candidates; the Company's expectations regarding its product designs, including with respect to patient benefit, duration, safety, effectiveness and tolerability; the results gathered from studies of Eupraxia's product candidates and their potential support for dosing and target population; the Company's beliefs with respect to treatment of knee osteoarthritis and eosinophilic esophagitis; the Company's initiation of its Phase 3 study; the Company's planned future milestones and timing thereof; potential market opportunity; and the potential and competitive advantages of Diffusphere™ in connection with the drug delivery process.

Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this presentation may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the possibility that the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the possibility that the Company's technology may not be successful for its intended use; the fact that the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the possibility that the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications;

The possibility that the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the possibility that the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the fact that the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of

tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the fact that the Company relies on external contract research organizations to provide clinical and non-clinical research services; the possibility that the Company may not be able to successfully execute its business strategy; the fact that the Company will require additional financing, which may not be available; the fact that any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (www.sedarplus.com) and EDGAR (www.sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

All of the forward-looking statements in this presentation are qualified by these cautionary statements and the Company cannot assure that the results or developments anticipated by management will be realized or even if realized, will have the expected consequences to, or effects on, the Company or its business, prospects, financial condition, results of operations or cash flows. Readers are cautioned not to place undue reliance on the forward-looking statements in making any investment decision.

MARKET AND INDUSTRY DATA

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to share value and other data about our industry. The Company obtained this data from its own internal estimates and research and from academic and industry research, publications, surveys, and studies conducted by third parties, including a research report conducted by Clearview that the Company commissioned. These data involve a number of assumptions and limitations, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed in our public filings on SEDAR+ and EDGAR. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and us. The Company has not independently verified any of the data from third party sources referred to in this presentation or ascertained the underlying assumptions relied upon by such sources. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

Eupraxia is Poised for Significant Growth in 2026



Compelling EP-104GI clinical data

from the ongoing RESOLVE trial in Eosinophilic Esophagitis



Well-capitalized

into H2 2028, beyond key catalysts with over \$140M¹ cash and short-term assets



Near-term catalysts:

- Quarterly readouts of Phase 1b/2a data
- Interim Phase 2b trial data expected in Q4 2026
- Initiation of a clinical trial in an additional indication in H2 2026



Growing pipeline

with additional indications using the Diffusphere™ platform

EP-104GI: Executive Summary

Significant Opportunity

- EoE is estimated to affect over **one million** people in the US by 2030
- Target Product Profile (TPP) supports market leading potential in a **multi-billion dollar market**

Compelling Clinical Data


Clinical data suggests potential for best-in-class:

-  Symptom improvement
-  Histologic improvement
-  Tolerability
-  Durability



Patient Convenience

Potential for annual injections during routine endoscopy

Precise Delivery

Targeted drug placement at site of diseased tissue

Locally Released

Designed to minimize systemic exposure

- Active ingredient is well characterized and has a **known Mechanism of Action** in EoE
- Established PK profile and durability with **Diffusphere™ technology**
- Five patent families granted around the world: earliest expiry 2030's, latest expiry mid-2040's

Differentiated

Mitigated Development Risk

Eupraxia's Diffusphere™ Drug Delivery Platform


Is intended to deliver the *right dose* of drug, in the *right place*, for the *right duration*



Eupraxia's Diffusphere™ coats an active drug compound within a polymer membrane



Shown clinically to release the drug core at a near-constant rate¹⁻³





Lead clinical candidate EP-104GI

A controlled-release fluticasone propionate formulation designed to be injected into esophagus.²

Currently being studied as a potential *once-per-year* treatment.

EP-104GI

Eosinophilic Esophagitis



New Treatment Options are Needed for Eosinophilic Esophagitis (EoE)



Chronic and progressive disease of the esophagus¹




One of the most common causes of **swallowing difficulties** (dysphagia) and **food impaction** in adults²



Characterized by **local inflammation** potentially leading to **narrowing and stiffness of the esophagus** if untreated¹



Prevalence **grew over 5x** ↑ since 2009³ with an estimated **1 million** patients in the US estimated by 2030⁴



Treatment Options in EoE¹

- Pharmacological (on-label and off-label) and diet options are used for the treatment of EoE¹
- **Some studies suggest current options can be limited by:**
 - Poor treatment adherence (less than 45%)^{6,7}
 - Class-related or off-target adverse effects⁷⁻⁹

Novel treatment options are needed to improve outcomes, tolerability and patient adherence

Targeting the Complex Inflammatory Cascade in EoE



EoE results from an **abnormal inflammatory response** in the esophagus¹




Inflammation and fibrosis (scar tissue) leads to swallowing difficulties, pain and, eventually strictures



Corticosteroids target the EoE inflammatory cascade, but delivery to esophageal tissue can be challenging²

EP-104GI targets key drivers of EoE through local, long-term fluticasone propionate release³

Model of EP-104GI Mode of Action In EoE⁴




Optimizing Coverage in the Esophagus




EP-104GI is injected through an endoscope during a routine endoscopy



Submucosal delivery is intended to broadly release fluticasone throughout the esophagus



Model of Esophageal Coverage by EP-104GI Injection Pattern



EP-104GI is Designed to Integrate Seamlessly with Disease Management

Annual endoscopies are recommended by current guidelines to monitor EoE¹

- A single EP-104GI administration led to fluticasone propionate release and clinical remission was observed in patients for **12 months** in early clinical trials²




Esophageal injections are established in endoscopists practice

- Similar injections are frequently used for other GI conditions.³
- Procedural **billing codes (CPT) already exist** for esophageal injections.⁴

% of Patients

Market survey indicates that patients undergo regular endoscopy⁵



The Potential to Transform EoE Management

Available data suggests EP-104GI is well positioned to be integrated with the standard of care



Annual Injection During Routine Endoscopy

- Aligning with recommended EoE endoscopy schedule.
- Intended to improve medical adherence.



Targeted Release in Esophageal Tissue

- Potential to improve dysphagia and tissue health for a year after a single administration.¹



Limited Systemic Exposure

- Potentially reduced risk of class-related adverse events
(ex. adrenal suppression, GI candidiasis).¹



Clinically Validated Mechanism of Action

- API already used in treatment in EoE.
- Early data shows impact on inflammation and fibrosis.¹

What Does Success Look Like?

Development goals for a new treatment option


Efficacy	1. Durability:	9-12 month dosing frequency
	2. Symptoms (SDI):	Achieve clinical remission in at least 40% of patients
	3. Tissue Health (EoEHSS):	Meaningful reduction in stage and grade (ex. greater than 0.2)
Safety & Tolerability	4. Safety Outcomes:	Less than 2% of patients experience oropharyngeal candidiasis
	5. Glucose and cortisol levels:	No clinically significant changes or spikes

Physicians, Payers and Patients express a strong willingness to adopt a treatment with this target product profile¹

High-Value Commercial Opportunity

Significant Market Size


U.S. EoE Patients in 2030^{1,2,3}



Market Leader Potential


EP-104GI Estimated Market Share⁴

30% - 40%
of PPI Refractory Patients



Premium Pricing Environment

Annual Wholesale Acquisition Cost^{5,6}



Costs of existing approved EoE treatments in the U.S.^{5,6}

Potential to capture a significant share of a growing multi-billion dollar market

1. ClearView Market Research: Estimates ~60% of diagnosed patients are in 2L/3L (i.e., not well managed on PPIs or diet) (Lucendo. 2025; Stakeholder Interviews), 2. GlobalData Epidemiology Database: Eosinophilic Esophagitis, US, Lifetime Diagnosed Prevalent Cases, All ages, Men and Women (accessed Feb 2026) 3. Internal analysis: literature estimates diagnosed EoE prevalence of ~143 per 100 K patients in 2024, growing at a rate of ~11 per 100 K year-over-year (Dellon et al. (2025) AJG 120(1):31-59). 4. ClearView Market Research. 30-40% of 2L/3L patients, assuming 12mo durability (June 2025) 5. ClearView Market Research. Estimated Eohillia WAC varies based on dosing as label indicates 12-week dosing with Source: Eke. Hellenic SocGastro. 2020; BlueCross Blue Shield Website; Cigna Website; Kaiser Permanente Website; United Healthcare Website; Navlin; Stakeholder Interviews. Additional discount programs may exist; 6. Internal analysis: 52-week WAC for Dupixent estimated from bi-weekly WAC of \$4,193.03 USD for adult patients as reported on <https://www.dupixent.com/support-savings/copy-card-insurance> (accessed Feb 2026). Additional discount program may exist;

Resolve

Clinical Trial of EP-104GI In EoE



RESOLVE (NCT05608681): Phase 1b/2 Trial of EP-104GI in EoE


Multicenter, open-label, dose-escalation and optimization trial

Part I – Dose Escalation

- Single administration of EP-104GI at baseline
- Progressively higher number of injections to increase therapeutic coverage area of the esophagus
- Post-administration follow-up
 - 24 weeks (4×1mg - 12×2.5mg)
 - 52 weeks (subsequent dose levels)

Endpoints

- Pharmacokinetics
- Safety & Tolerability
- Symptoms of EoE
 - Straumann Dysphagia Index (SDI)
- Esophageal Inflammation & Remodeling
 - Peak Eosinophil Counts (PEC)
 - EoE Histology Scoring System (EoEHSS)
 - Eosinophilic Esophagitis Reference Score (EREFS)




RESOLVE Part 1 - Dose Escalation

n=31

Cohort-Level Pharmacokinetics

Stable drug release out to 12 months with low C_{max}




Clinical Remission Rates with EP104-GI

Large percentage of patients obtaining durable, meaningful clinical improvement


SDI Clinical Remission Rates Over Time: Cohorts 4-9

Percentage of patients achieving ≥ 3 -point reduction in SDI score



SDI by Cohort


Strongest SDI reduction observed in doses being tested in the placebo-controlled Phase 2b



Tissue Health (EoEHSS)


Improved with increasing local dose and exposure

Decrease from baseline in EoEHSS Composite (0-1) Grade and Stage by dose/site




Histologic Remission

Remission rates improved with dose and time



Histologic Remission



Remission rates improved with dose and time



RESOLVE Trial: Well-tolerated Over 230 Months of Patient Follow-up

No cases of oropharyngeal candidiasis, glucose derangement, or abnormal cortisol levels

- No serious drug related AEs
- **No cases of oropharyngeal candidiasis**
- Procedural AEs resolved quickly without treatment



Company data current as of Apr 21, 2026

RESOLVE (NCT05608681): Phase 1b/2 Trial of EP-104GI in EoE

Multicenter, open-label, dose-escalation and optimization trial


CURRENTLY RECRUITING

Part II – Dose Optimization

- Single administration of EP-104GI at baseline
- Post-administration follow-up: 52 weeks
 - 1:1:1 (Dose A : Dose B : Placebo)
 - 24-week placebo crossover

Endpoints

- Pharmacokinetics
- Safety & Tolerability
- Esophageal Inflammation & Remodeling
 - Peak Eosinophil Counts (PEC)
 - EoE Histology Scoring System (EoEHSS)
 - Eosinophilic Esophagitis Reference Score (EREFS)
- Dysphagia Symptoms
 - Straumann Dysphagia Index (SDI)
 - Dysphagia Score Questionnaire (DSQ)



RESOLVE Part 2 - Dose Optimization

Proposed Development Path of EP-104GI in EoE

Upcoming Catalysts


- **Part I – Phase 1b/2a / Dose Escalation**
 - Quarterly Data expected through Q3 2026
- **Part II – Phase 2b / Dose Optimization**
 - Interim data expected Q4 2026
- **Anticipated End of Phase 2 meeting with the FDA expected H1 2027**
- **Mid-2027: Aim to Commence Single Registrational Phase 3 study**
 - n=150-300 patients, based on the Phase 2 data
 - Placebo controlled single dose investigating efficacy and safety out to 52 weeks

Corporate Overview



Strategic roadmap to a synergistic portfolio

Forming a strategic portfolio of hyper-local ultra long-acting therapeutics



Market Data

Exchange: Ticker	NASDAQ: EPRX, TSX: EPRX ¹
Share Price on Nasdaq (May 12 th , 2026)	\$7.61
Common Shares Outstanding (May 12 th , 2026)	65.3 million
Fully Diluted Common Shares (May 12 th , 2026)	84.8 million
Market Capitalization (May 12 th , 2026) ²	\$497 million
Board & Mgmt. Ownership (May 12 th , 2026)	~11% / ~21% (FD)
Cash and Short-term Assets (March 31 st , 2026)	\$142.1 million ³